
1st International Electronic Conference on Biomedicine
1–26 Jun 2021
Therapeutic Targets, Therapeutic Strategies, Naturally Driven Biomedicines, Pharmaceuticals, Biopharmaceutical Products
- Go to the Sessions
-
- S1. Nanomedicine and Precision Medicine
- S2. Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals
- S3. Cancer Therapeutics
- S4. Metal-based Therapeutics in Preclinical and Clinical Developments
- S5. Oncolytic Virus-Mediated Immunotherapy
- S6. Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure
- S7. Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry
- S8. Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants
- S9. Translational Biomarkers in Clinical Biomedicine and Precision Medicine
- S10. G-protein-coupled Receptor Family
- S11. Microbiota, Probiotics and Nutraceuticals: Preventive and Therapeutic Potential
- Event Details
All participants of ECB2021 are welcome to submit the extended work to the Biomedicines Special Issue "Selected Papers in the 1st International Electronic Conference on Biomedicine (ECB 2021)".
We are pleased to announce the winners of the Best Paper Award and Best Poster Award:
Best Paper Award:
“Drug Targets, and Prognosis Markers, and Therapy Efficacy Predictors in Breast Cancer Treatment Cancer Stem Cells and Somatic Stem Cells as Potential New”
by Evgenii Skurikhin et al.
Best Poster Award:
“Antibacterial assessment of sodium alginate/gelatin films loaded with propolis extract”
by Natália C. Homem et al.
Welcome from the Chairs
Dear Colleagues,
It is my pleasure to invite you to join the 1st International Electronic Conference on Biomedicine (ECB 2021) that is hosted online by: https://ecb2021.sciforum.net.
ECB 2021 will present the latest research related to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products.
Topics of interest include but are not limited to:
- Nanomedicine and Precision Medicine
- Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals
- Cancer Therapeutics
- Metal-based Therapeutics in Preclinical and Clinical Developments
- Oncolytic Virus-mediated Immunotherapy
- Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure
- Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry
- Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants
- Translational Biomarkers in Clinical Biomedicine and Precision Medicine
- G-protein-coupled Receptor Family
- Microbiota, Probiotics and Nutraceuticals: Preventive and Therapeutic Potential
ECB 2021 seeks to fulfill this need by offering a completely digital (online) method for running a scientific conference. ECB 2021 will allow its participants to share their latest research results and receive near-instantaneous feedback from biomedical researchers throughout the world through online question and answer sessions and discussion groups. In this way, ECB 2021 will serve as a platform for advancing the state-of-the-art in biomedicines. There is no cost to participate in ECB 2021.
All submitted abstracts will be evaluated by the conference committee. Upon acceptance of their abstract, authors will contribute an extended abstract for the conference proceedings and a slide presentation of their work. Selected papers (need 50% extension compared with the proceedings papers) will be considered for publication in the special issue "Selected Papers in the 1st International Electronic Conference on Biomedicine (ECB 2021)", with a 20% discount on the APC after peer-review.
I hope you will choose to be a part of this exciting conference and present your most transformative research on biomedicine.
Conference Secretariat
Ms. Nicole Peng
MDPI Branch Office, Wuhan
E-mail: [email protected]
Ms. Penny Zhang
MDPI Branch Office, Wuhan
E-mail: [email protected]
Ms. Stefanie Li
MDPI Branch Office, Wuhan
E-mail: [email protected]
Conference Chairs

Professor Shaker A. Mousa
Albany College of Pharmacy and Health Sciences, Rensselaer, USA

Dr. Veronique Baud
Faculté de Pharmacie, Paris, France
Conference Committee

Professor Shaker A. Mousa
Albany College of Pharmacy and Health Sciences, Rensselaer, USA

Dr. Muhammad Hanif
The University of Auckland, Auckland, New Zealand

Dr. Zong Sheng Guo
The University of Pittsburgh Cancer Institute, and University of Pittsburgh School of Medicine, Pittsburgh, USA

Dr. Jacek M. Kwiecien
McMaster University, Ontario, Canada

Dr. Masaru Tanaka
University of Szeged, Szeged, Hungary

Professor Alexander Seifalian
The London BioScience Innovation Centre, London, United Kingdom

Dr. Allan Stensballe
Alborg University, Aalborg, Denmark

Professor Ujendra Kumar
The University of British Columbia, Vancouver, Canada

Professor Ciro Isidoro
Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy
Session Chairs

Professor Shaker A. Mousa
Albany College of Pharmacy and Health Sciences, Rensselaer, USA
Nanomedicine and Precision Medicine; Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals

Dr. Veronique Baud
Faculté de Pharmacie, Paris, France
Cancer Therapeutics

Dr. Muhammad Hanif
The University of Auckland, Auckland, New Zealand
Metal-based Therapeutics in Preclinical and Clinical Developments

Dr. Zong Sheng Guo
The University of Pittsburgh Cancer Institute, and University of Pittsburgh School of Medicine, Pittsburgh, USA
Oncolytic Virus-Mediated Immunotherapy

Dr. Jacek M. Kwiecien
McMaster University, Ontario, Canada
Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure

Dr. Masaru Tanaka
University of Szeged, Szeged, Hungary
Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry

Professor Alexander Seifalian
The London BioScience Innovation Centre, London, United Kingdom
Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants

Dr. Allan Stensballe
Alborg University, Aalborg, Denmark
Translational Biomarkers in Clinical Biomedicine and Precision Medicine

Professor Ujendra Kumar
The University of British Columbia, Vancouver, Canada
G-protein-coupled Receptor Family

Professor Ciro Isidoro
Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy
Microbiota, Probiotics and Nutraceuticals: Preventive and Therapeutic Potential
Invited Speakers

Prof. Dr. David Bartlett
1. Department of Surgery, Drexel University College of Medicine, Pittsburgh, PA 15212, USA
2. AHN Cancer Institute
Sessions
S1. Nanomedicine and Precision MedicineS2. Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals
S3. Cancer Therapeutics
S4. Metal-based Therapeutics in Preclinical and Clinical Developments
S5. Oncolytic Virus-Mediated Immunotherapy
S6. Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure
S7. Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry
S8. Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants
S9. Translational Biomarkers in Clinical Biomedicine and Precision Medicine
S10. G-protein-coupled Receptor Family
S11. Microbiota, Probiotics and Nutraceuticals: Preventive and Therapeutic Potential
Video from Invited Speaker
Oncolytic Virus-Mediated Immunotherapy
by Prof.Dr. David Bartlett
List of accepted submissions (50)
Id | Title | Authors | Presentation Video | Presentation Pdf | |||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
sciforum-044756 | Serologic APE1/Ref-1: New biomarker for Vascular Inflammation in Atherosclerosis. | , , , | N/A | N/A |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) is a secretable multifunctional protein. Since the concept of APE1/Ref-1 secretion was established in 2013, several studies have demonstrated the usefulness of APE1/Ref-1 as a serological biomarker. However, the role of APE1/Ref-1 in atherosclerotic vascular inflammation is unclear. Herein, we investigated the role of APE1/Ref-1 in atherosclerotic apolipoprotein E (ApoE-/-) mice fed with a Western-type diet as an animal model of vascular inflammation. We found that serologic APE1/Ref-1 was strongly correlated with vascular inflammation in these mice. Neutrophil/lymphocyte ratio, endothelial cell/macrophage activation, and atherosclerotic plaque formation, reflected by atherosclerotic inflammation, were increased in the ApoE-/- mice fed with a Western-type diet. Correlation analysis showed a high correlation between plasma APE1/Ref-1 levels and neutrophil/lymphocyte ratio, a marker of systemic inflammation. We conclude that APE1/Ref-1 expression is upregulated in aortic endothelial cells/macrophages of atherosclerotic mice, and that plasma APE1/Ref-1 levels could predict atherosclerotic inflammation, it is a useful biomarker for vascular inflammation in atherosclerosis. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-044749 | Cytotoxic activity of gallic acid and myricetin against ovarian cancer cells by production of reactive oxygen species. | , , , , |
![]() |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Some studies demonstrate that gallic acid (GA) and myricetin (MYR) isolated from Rhus trilobata provide the therapeutic activity of the plant against cancer. However, few reports demonstrate that both compounds also could have therapeutic potential in ovarian cancer treatment. Therefore, to evaluate the cytotoxic activity of GA and MYR against ovarian cancer cells and to determine the possible action mechanism present is important. With this purpose, SKOV-3 ovarian adenocarcinoma cells (HTB-77™, ATCC®) were cultivated at 37°C with 5% CO2 according to supplier's instructions for determine the biological activity of GA and MYR by confocal/transmission electron microscopy, PI-flow cytometry, H2DCF-DA, MTT and Annexin V/PI assays. Possible molecular targets of the compounds were determined by Similarity Ensemble Approach model. Results showed that GA and Myr treatments decreased viability of SKOV-3 cells at 50 and 166 μg/mL respectively (p ≤ 0.05, ANOVA vs vehicle group); As well as morphological changed (cytoplasmatic reduction, nuclear chromatin condensation, cytoplasmic vesicles increment, polymerized actin, and stabilized tubulin), cell cycle arrest (GA: 8.3% G2/M and MYR: 78% G1), and apoptosis induction (GA: 18.9% and MYR: 8.1%), because to ROS generation (34 to 42%) for 24 h (p ≤ 0.05, ANOVA vs vehicle group). In silico studies demonstrated that GA and MYR interact with carbonic anhydrase and PI3K, respectively. As conclusions, GA and MYR show cytotoxic activity against SKOV-3 cells through ROS production, which modify the cytoskeleton and induce apoptosis mainly. Therefore, GA and Myr could be considered as a starting point for the development of novel anticancer agents. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-044793 | Ramucirumab as a second-line treatment for locally advanced or metastatic urothelial carcinoma: a meta-analysis of randomized clinical trials | , | N/A | N/A |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Improvement of treatment outcomes in patients with locally advanced or metastatic urothelial carcinoma represents an important unmet need, since survival remains poor in patients who progressed after first-line treatment. The purpose of this study was to investigate the effects of ramucirumab, a human monoclonal antibody which binds to VEGFR-2, in the treatment of locally advanced or metastatic urothelial carcinoma. A literature search of PubMed and CENTRAL was conducted. Outcomes of interest were overall survival (OS), progression-free survival (PFS) and rate of adverse events. Time-to-event outcomes were combined using the generic inverse-variance method and presented as hazard ratio (HR) with 95% confidence intervals (95%CI), while dichotomous events were combined using the Mantel-Haenszel method and presented as odds ratio (OR) with 95%CI. All analyses were performed in RevMan 5.3. Literature search identified two randomized controlled trials. Addition of ramucirumab to docetaxel resulted in a statistically significant improvement in PFS (HR=0.55, 95%CI 0.31-0.96, p=0.030), while the difference was not significant for OS (HR=0.86, 95%CI 0.71-1.04, p=0.12). Subgroup analysis by sex, age (<65 and ≥65 years), baseline hemoglobin (<10 g/dL and ≥10 g/dL), presence of visceral metastases and presence of liver metastases did not identify a subgroup in which improvement in OS was present. The difference in treatment-related grade≥3 adverse events was not significant (OR=1.47, 95%CI 0.95-2.27, p=0.08). Ramucirumab in addition to docetaxel significantly improved PFS in patients with locally advanced or metastatic urothelial carcinoma. Future studies are necessary to identify a subset of patients who might have a significant improvement in OS. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-044754 | Significant Implications of Apolipoprotein A1 (APOA1) polymorphic sequence variation in bladder cancer with its relative expression predictive for differential bladder tumor grades | , , , , , , , , , , | N/A | N/A |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Background: Apolipoprotein A1 (APOA1) is a potential biomarker due its variable concentration in different types of cancers. Objective: We for the first time evaluated the association between APOA1 -75 G/A, +83 C/T genotypes in tandem with APOA1 protein expression in urine samples to find out risk and potential relationship for differentially expressed urinary proteins and APOA1 genotypes. Design: The study included 108 cases of bladder tumors and 150 healthy controls that were frequency matched to cases with respect to age, sex and smoking status. Genotyping was performed by PCR-RFLP and urinary expression of APOA1 protein was done by ELISA. Results: Bladder tumor cases were significantly associated with APOA1-75 AA genotype (p<0.05) while as APOA1+83 CT heterozygotes showed association with cases (p<0.05). The overall distribution of different haplotypes showed a marked difference between cases and controls in GT when compared with wild type GC (p<0.03). Bladder tumor cases that carried variant genotype APOA1-75AA presented more (70.0%) with higher expression (≥20ng/ml) of APOA1 urinary protein and differed significantly against wild typeGG (p=0.03). Again, in low grade bladder tumors, urinary APOA1 protein significantly presented more (52.4% vs. 15.4% high grade) with higher expression (≥20ng) while high grade tumor cases (84.6% vs. 47.5% low grade) showed lower APOA1expression (<20ng/ml) (O.R= 6.08, p=0.002). Conclusions: We found a strong association between APOA1-75G/A and risk for bladder tumor and its relation to urinary protein expression that substantiates its possible role as a marker for risk assessment of the disease and promising diagnostic marker for different grades of malignant bladder tumors Key Words: Bladder cancer; APOA1; Genotype; Allele; Protein expression; Haplotype |
|||||||||||||||||||||||||||||||||||||||||
sciforum-044773 | Structural and biological evaluation of novel multi-target compound with potential application in the treatment of schizophrenia | , , , , , , , , , | N/A |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||
In the process of searching for novel compounds with antipsychotic properties, structure-based virtual screening was conducted [1]. Among found dopamine D2 receptor antagonists, the compound D2AAK3 with 115 nM affinity for D2 receptor was identified. It also shows nanomolar or low micromolar affinity for D1, D3, 5-HT1A, 5-HT2A and 5-HT7 receptors, what makes it a good candidate for a multi-target drug. Interactions of D2AAK3 with its molecular targets at the molecular level were studied in silico by performing homology modeling, molecular docking and molecular dynamics. The main contact of D2AAK3 with all studied receptors is the electrostatic interaction between the proton attached to the nitrogen atom of the ligand and the conserved Asp(3.32), what is typical for orthosteric binding mode in aminergic GPCRs. Behavioral studies [2] performed for D2AAK3 revealed that it decreases amphetamine-induced hyperactivity measured as spontaneous locomotor activity in mice, improves memory consolidation after acute treatment in passive avoidance test and exhibits anxiogenic activity 30 minutes after acute treatment in mice in elevated plus maze (this effect was reversed 60 minutes after administration of D2AAK3). Further optimization of reported compound, toward obtaining molecule with properties resembling atypical antipsychotics, will be conducted.
References:
|
Instructions for Authors
Submissions should be submitted by the authors online by registering at https://ecb2021.sciforum.net/, and using the “Submit Abstract” function once logged into system.
- Scholars interested in participating with the conference can submit their abstract (about 200–250 words covering the areas of manuscripts for the proceedings issue) online at this website up to 16 March 2021.
- The Conference Committee will conduct a pre-evaluation, based on the submitted abstract, of whether the contribution from the authors of the abstract will be welcome for the 1st International Electronic Conference on Biomedicine. All authors will be notified by 31 March 2021 about the acceptance of their abstract.
- If the abstract is accepted for this conference, the author is asked to submit the manuscript optionally along with a PowerPoint and/or video presentation of his/her paper (only PDF), up to the submission deadline of 30 April 2021.
- The conference proceedings papers and presentations will be available at https://ecb2021.sciforum.net for discussion during the time of the conference, 1–26 June 2021, and will be published in Journal Proceedings.
- After the conference, the authors are encouraged to submit a full manuscript based on the proceedings to the Biomedicines Special Issue "Selected Papers in the 1st International Electronic Conference on Biomedicine (ECB 2021)" with a 20% discount on the Article Processing Charges.
Manuscripts for the proceedings issue must have the following organization:
First page:
- Title
- Full author names
- Affiliations (including full postal address) and authors’ e-mail addresses
- Abstract (200–250 words)
- Keywords
- Introduction
- Methods
- Results and Discussion
- Conclusions
- (Acknowledgements)
- References
Manuscripts should be prepared in MS Word or any other word processor and should be converted to PDF format before submission. The publication format will be PDF. The manuscript should be at least 3 pages (incl. figures, tables, and references) and should not exceed 6 pages.
Presentation Slides
Authors are encouraged to prepare a presentation in PowerPoint or similar software, to be displayed online along with the manuscript. Slides, if available, will be displayed directly in the website using the proprietary slides viewer at Sciforum.net. Slides can be prepared in exactly the same way as for any traditional conference where research results can be presented. Slides should be converted to PDF format before submission so that we can easily and automatically process them for online display.
Video Presentations
Besides their active participation within the forum, authors are also encouraged to submit video presentations. The video should be no longer than 20 minutes and be prepared in one of the following formats:
- MOV
- MPEG4
- MP4
- AVI
- WMV
- MPEGPS
- FLV
Authors that wish to present only a poster, i.e., without a proceedings paper, can do so in section I. Posters will be available on the conference website during and after the event. Similarly to papers presented at the conference, participants will be able to ask questions and make comments about the posters. Posters that are submitted without a paper will not be included in the proceedings of the conference.
Submission: Manuscripts should be submitted online at https://ecb2021.sciforum.net by registering and logging in to this website.
Accepted File Formats
- MS Word: Manuscript prepared in MS Word must be converted into a single file before submission. When preparing manuscripts in MS Word, the 1st International Electronic Conference on Microbiology Microsoft Word template file (see download below) must be used. Please do not insert any graphics (schemes, figures, etc.) into a movable frame which can superimpose the text and make layout very difficult.
1st International Electronic Conference on Biomedicine Microsoft Word template file
Manuscript Preparation
- Paper Format: A4 paper format, the printing area is 17.5 cm × 26.2 cm. The margins should be 1.75 cm on each side of the paper (top, bottom, left, and right sides).
- Paper Length: The conference proceedings paper should not be longer than 6 pages. The conference manuscript should be as concise as possible.
- Formatting/Style: The paper style of the journal Proceedings should be followed. You may download the template file to prepare your paper (see above). The full titles of the cited papers must be given. Reference numbers should be placed in square brackets [ ], and placed before punctuation; for example [4] or [1–3], and all the references should be listed separately and as the last section at the end of the manuscript.
- Authors List and Affiliation Format: Authors’ full first and last names must be given. Abbreviated middle name(s) can be added. For papers written by various contributors, a corresponding author must be designated. The PubMed/MEDLINE format is used for affiliations: complete street address information including city, zip code, state/province, country, and email address should be added. All authors who contributed significantly to the manuscript (including writing a section) should be listed on the first page of the manuscript, below the title of the article. Other parties who provided only minor contributions should only be listed under Acknowledgments. A minor contribution might be a discussion with the author, reading through the draft of the manuscript, or performing English corrections.
- Figures, Schemes, and Tables: Authors are encouraged to prepare figures and schemes in color. Full color graphics will be published free of charge. Figure and schemes must be numbered (Figure 1, Scheme I, Figure 2, Scheme II, etc.) and an explanatory title must be added. Tables should be inserted into the main text, and numbers and titles for all tables supplied. All table columns should have an explanatory heading. Please supply legends for all figures, schemes, and tables. The legends should be prepared as a separate paragraph of the main text and placed in the main text before a table, figure, or scheme.
Potential Conflicts of Interest
It is the authors’ responsibility to identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of clinical research. If there is no conflict, please state here “The authors declare no conflict of interest”. This should be conveyed in a separate “Conflict of Interest” statement preceding the “Acknowledgments” and “References” sections at the end of the manuscript. Financial support for the study must be fully disclosed under the “Acknowledgments” section.
Copyright
MDPI, the publisher of the Sciforum.net platform, is an open access publisher. We believe that authors should retain the copyright to their scholarly works. Hence, by submitting a Communication paper to this conference, you retain the copyright of your paper, but you grant MDPI the non-exclusive right to publish this paper online on the Sciforum.net platform. This means you can easily submit your paper to any scientific journal at a later stage and transfer the copyright to its publisher (if required by that publisher).
Call for Papers
The 1st International Electronic Conference on Biomedicine will be held on 1–26 June 2021. ECB 2021 aims to promote and advance the exciting and rapidly changing field of Biomedicine. All proceedings will be held online at https://ecb2021.sciforum.net.
Topics of interest include, but are not limited to:
- Nanomedicine and Precision Medicine
- Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals
- Cancer Therapeutics
- Metal-based Therapeutics in Preclinical and Clinical Developments
- Oncolytic Virus-mediated Immunotherapy
- Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure
- Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry
- Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants
- Translational Biomarkers in Clinical Biomedicine and Precision Medicine
- G-protein-coupled Receptor Family
- Microbiota, Probiotics and Nutraceuticals: Preventive and Therapeutic Potential
ECB 2021 is an electronic conference sponsored by Biomedicines. Participation is free of charge for authors and attendees. Accepted papers will be gathered in the proceedings of the conference. Selected extended versions of the papers will be published in a Special Issue of Biomedicines and undergo full peer review (ISSN 2227-9059; impact factor: 4.717 (2020)) with a 20% discount on the article processing charge. ECB 2021 offers you the opportunity to participate in this international, scholarly conference without the concerns or expenditure of travel—all you need is your computer and access to the internet. We would like to invite you to attend this conference and present your latest work.
Abstracts (in English) should be submitted online by 16 March 2021 at https://ecb2021.sciforum.net. For accepted abstracts, the proceedings can be submitted by 30 April 2021. The conference will be held on 1–26 June 2021.
Paper Submission Guidelines
For information about the submission procedure and preparation of a full presentation, please refer to the "Instructions for Authors".
Time Schedule
- Abstract Submission: 16 March 2021
- Notification of Acceptance: 31 March 2021
- Paper Submission Deadline: 30 April 2021
- Conference Open: 1–26 June 2021
We thank you in advance for your attendance of this conference and look forward to a stimulating exchange.
Event Awards
To acknowledge the support of the conference esteemed authors and recognize their outstanding scientific accomplishments, we are pleased to launch the Best Paper Award and Best Poster Award.
The Awards
The Best Paper Award is presented to the paper judged to make the most significant contribution to the conference.
The Best Poster Award was established to recognize the scientific merit exhibited in poster presentation and preparation.
Terms and Conditions:
Best Paper Award
As a sponsor, Biomedicines would like to award the best paper as elected by the conference committee. The award will consist of 500 Swiss Francs. We look forward to posting your contributions.
Criteria for Evaluation of Best Paper Award:
- Full paper must be submitted to ECB2021;
- Originality/novelty of the paper;
- Significance of content;
- Scientific soundness;
- Interest to the readers;
- English language and style.
Evaluation
- Each Evaluation Committee member will give an assessment for each applicant in terms of the criteria outlined above;
- The total score for each presentation will be ranked from highest to lowest;
- If two or more authors receive the same score, further evaluation will be carried out;
- All decisions made by the Evaluation Committee are final.
Best Poster Award
As a sponsor, Biomedicines would like to grant an award (500 Swiss Francs) for the best poster presented at the conference. This prize is awarded by a jury to the best designed poster presented at the conference.
Posters should have the following information.
- Title (with authors and affiliations)
- Introduction/Objectives/Aims
- Methods
- Results
- Conclusion
- References
- Acknowledgements
- Contact information
- A 3-minute video presentation
During the conference, the chair is invited to judge the quality of the 3-minute video presentation and poster. Criteria for judgement of the presentation will be the ability to summarize the content of the work and motivate the interest in looking at the poster. In addition, the clarity of poster and appearance quality will be considered.
S1. Nanomedicine and Precision Medicine
S2. Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals
S4. Metal-based Therapeutics in Preclinical and Clinical Developments
Session Chair
Dr. Muhammad Hanif, The University of Auckland, Auckland, New Zealand
S6. Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure
Show all published submissions (1) Hide published submissions (1)
Submissions
List of Papers (1) Toggle list
S7. Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry
S8. Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants
S9. Translational Biomarkers in Clinical Biomedicine and Precision Medicine
S10. G-protein-coupled Receptor Family
Show all published submissions (7) Hide published submissions (7)
Submissions
List of Papers (7) Toggle list